Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + carboplatin + pembrolizumab is a combination regimen used in the treatment of several cancers, including non-small cell lung cancer (NSCLC), endometrial carcinoma, head and neck squamous cell carcinoma (HNSCC), and breast cancer. Paclitaxel is a chemotherapy drug classified as an anti-microtubule inhibitor that disrupts microtubule function during cell division, leading to apoptosis of rapidly dividing tumor cells. Carboplatin is an alkylating agent that causes DNA crosslinking and damage, inhibiting DNA synthesis and function. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting programmed death-1 (PD-1) on T cells; it blocks the interaction with PD-L1/PD-L2 ligands on tumor cells or other immune cells, thereby enhancing T-cell mediated antitumor immunity. This combination leverages both cytotoxic chemotherapy and immunotherapy for synergistic antitumor effects[7][8][10].
- Brand names
- ParaplatinTaxolKeytruda
- Other names
- paclitaxel + carboplatin + pembrolizumabpaclitaxel/carboplatin/pembrolizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on paclitaxel + carboplatin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + pembrolizumab.